US 11,945,832 B2
Psilocybin and O-acetylpsilocin, salts and solid state forms thereof
Samuel Clark, New York, NY (US)
Filed by Terran Biosciences Inc., New York, NY (US)
Filed on Sep. 15, 2023, as Appl. No. 18/468,583.
Application 18/468,583 is a continuation of application No. 18/147,066, filed on Dec. 28, 2022.
Application 18/147,066 is a continuation of application No. PCT/US2022/079752, filed on Nov. 11, 2022.
Claims priority of provisional application 63/357,378, filed on Jun. 30, 2022.
Claims priority of provisional application 63/357,512, filed on Jun. 30, 2022.
Claims priority of provisional application 63/326,421, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,713, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,522, filed on Apr. 1, 2022.
Claims priority of provisional application 63/326,364, filed on Apr. 1, 2022.
Claims priority of provisional application 63/324,878, filed on Mar. 29, 2022.
Claims priority of provisional application 63/321,593, filed on Mar. 18, 2022.
Claims priority of provisional application 63/319,746, filed on Mar. 14, 2022.
Claims priority of provisional application 63/316,952, filed on Mar. 4, 2022.
Claims priority of provisional application 63/315,901, filed on Mar. 2, 2022.
Claims priority of provisional application 63/311,878, filed on Feb. 18, 2022.
Claims priority of provisional application 63/310,987, filed on Feb. 16, 2022.
Claims priority of provisional application 63/310,984, filed on Feb. 16, 2022.
Claims priority of provisional application 63/305,642, filed on Feb. 1, 2022.
Claims priority of provisional application 63/305,643, filed on Feb. 1, 2022.
Claims priority of provisional application 63/300,961, filed on Jan. 19, 2022.
Claims priority of provisional application 63/300,957, filed on Jan. 19, 2022.
Claims priority of provisional application 63/285,050, filed on Dec. 1, 2021.
Claims priority of provisional application 63/280,294, filed on Nov. 17, 2021.
Claims priority of provisional application 63/280,300, filed on Nov. 17, 2021.
Claims priority of provisional application 63/279,005, filed on Nov. 12, 2021.
Claims priority of provisional application 63/278,943, filed on Nov. 12, 2021.
Prior Publication US 2024/0010663 A1, Jan. 11, 2024
Int. Cl. C07F 9/572 (2006.01)
CPC C07F 9/5728 (2013.01) [C07B 2200/13 (2013.01)] 18 Claims
 
1. A crystalline form of psilocybin edisylate (Form A) that is characterized as having:
an X-ray powder diffraction (XRPD) diffractogram with characteristic peaks at 7.0±0.2° 2-Theta, 9.1±0.2° 2-Theta, 11.6±0.2° 2-Theta, 13.1±0.2° 2-Theta and 13.4±0.2° 2-Theta, as measured with Cu Kα radiation, or
an XRPD diffractogram with characteristic peaks at 9.0±0.2° 2-Theta, 11.6±0.2° 2-Theta, 13.0±0.2° 2-Theta, 16.4±0.2° 2-Theta and 18.5±0.2° 2-Theta, as measured with Cu Kα radiation.